Hyo-Soo Kim, ACC 2023: Guidelines for the use of short-term dual antiplatelet therapy after coronary intervention

The guidelines for the use of short-term dual antiplatelet therapy (DAPT) after coronary intervention vary depending on the patient’s clinical situation and the type of intervention performed. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) to discuss the current guidelines for the use of short-term DAPT after percutaneous coronary intervention and the current unmet needs.

The abstract entitled ‘Comparison Of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using The Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The Host-idea Randomized Clinical Trial‘ was presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023

Interviews in this series:

Prof. Hyo-Soo Kim discusses findings from the HOST IDEA trial – Short-term dual antiplatelet therapy non-inferior to 12 Months after PCI with third-generation drug-eluting stents

Questions:

1. What are the guidelines for the use of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), and what are the current unmet needs? (0:05)

Disclosures: Hyo-Soo Kim has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ACC 2023

Access more content on Heart Failure here

Transcript